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The purpose of the study was to identify a comprehensive prognostic system of pretreatment clinical parameters in 425 patients (pts)
with metastatic renal-cell carcinoma treated with different subcutaneous (s.c.) recombinant cytokine-based home therapies in
consecutive trials. Treatment consisted of (A) s.c. interferon-a2a (INF-a), s.c. interleukin-2 (IL-2) (n¼102 pts), (B) s.c. IFN-a2a, s.c. IL-
2, and i.v. 5-fluorouracil (5-FU) (n¼235 pts) or (C) s.c. IFN-a2a, s.c. IL-2, and i.v. 5-FU combined with p.o. 13-cis-retinoic acid
(13cRA) (n¼88 pts). Kaplan–Meier survival analysis, log-rank statistics, and Cox regression analysis were employed to identify risk
factors and to create a multiple risk factor model. The following pretreatment risk factors were identified by univariate analysis: (1)
three and more metastatic sites, (2) presence of liver, lymph node or bone metastases, (3) neutrophil count X6500cellsml
 1, (4)
serum lactate dehydrogenase level (LDH) X220Ul
 1, and (5) serum C-reactive protein level (CRP) X11mgl
 1. Cox regression
analysis with forward stepwise variable selection identified neutrophil count as the major prognostic factor (hazard ratio¼1.9,
Po0.001), while serum levels of LDH and CRP, time between diagnosis of tumour and onset of metastatic disease, number of
metastatic sites, and bone metastases were significant but somewhat less important prognostic variables within the multiple risk factor
model (hazard ratio p1.5). Patients were assigned to one of the three risk groups according to cumulative risk defined as the sum of
simplified risk s.c.ores for six pretreatment variables. Low-, intermediate-, and high-risk patients achieved a median overall survival of
32+ months (95% CI 24, 43; 5-year survival of 27%), 18+ months (95% CI 15, 20; 5-year survival of 11%), and 8+ months (95% CI 6,
10; 5-year survival of 5%), respectively. These prognostic categories are helpful both in individual patient care and in the assessment of
patients entering prospective clinical trials.
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Patients (pts) with untreated metastatic renal-cell carcinoma have
an overall median survival of no more than 12 months and a 5-year
survival of less than 10%. While renal-cell carcinoma responds
poorly to single-agent chemotherapy or hormonal therapy,
immunotherapies with subcutaneous (s.c.) recombinant interleu-
kin-2 (IL-2) alone or in combination with s.c. recombinant
interferon-a (INF-a) yielded significant therapeutic efficacy in
renal-cell carcinoma (Atzpodien et al, 1990, 2001, 2002; Sleijfer
et al, 1992).
In previous studies, a variety of prognostic staging factors,
notably, performance status, recent weight loss, disease-free
interval, pretreatment erythrocyte sedimentation rate (ESR),
lactate dehydrogenase (LDH), neutrophils, haemoglobin, extra-
pulmonary and bone metastases, and a number of metastatic sites
were identified as important indicators for survival in metastatic
renal-cell carcinoma patients (Elson et al, 1988; Palmer et al, 1992;
Lopez-Ha ¨nninen et al, 1996; Gelb, 1997; Culine et al, 1998;
Hoffmann et al, 1999; Motzer et al, 1999, 2002).
Here, we develop a comprehensive new prognostic system for
metastatic renal carcinoma patients, by retrospective analysis. All
patients were treated with outpatient immunotherapy comprising
s.c. IL-2 and s.c. INF-a.
PATIENTS AND METHODS
Patients
Between November 1988 and February 1998, 425 patients with
progressive metastatic renal-cell carcinoma were entered on
consecutive clinical trials and received either IFN-a2a, IL-2
(therapy A, n¼102 pts), IFN-a2a, IL-2, and 5-FU (therapy B,
n¼235 pts) or IFN-a2a, IL-2, and 5-FU combined with 13cRA
(therapy C, n¼88 pts). Median follow-up of these patients was 20+
months (range 0–157+ months). Pretreatment included radical
tumour nephrectomy (n¼412), chemotherapy (n¼5), immu-
notherapy (n¼47), chemoimmunotherapy (n¼8), and hormone
therapy (n¼32).
Since all treatment regimens were designed to be administrated
at home, selection of patients with good or excellent performance
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lstatus was required. Criteria for entry into the study were:
histologically confirmed metastatic renal-cell carcinoma; an
expected survival duration of more than 3 months; Karnofsky
performance status 480%; age between 18 and 80 years; white
blood cell count 43500ml
 1; platelet count 4100000ml
 1;
haematocrit 430%; serum bilirubin and creatinin o1.25 of the
upper normal limit. Exclusion criteria included evidence of
congestive heart failure, severe coronary artery disease, cardiac
arrhythmias, symptomatic CNS disease or seizure disorders,
human immunodeficiency virus infections or positivity for
hepatitis B surface antigen or chronic hepatitis, or concomitant
corticosteroid therapy. In all patients treated, no chemotherapy,
immunomodulatory treatment, or steroid therapy had been
performed during the previous 4 weeks. Pregnant and lactating
woman were excluded.
The clinical studies were approved by the institutional review
board of the Medizinische Hochschule Hannover; written in-
formed consent was obtained from all patients prior to entry into
the study.
Treatment design
Patients were treated in an outpatient setting. All patients received
outpatient s.c. IFN-a2a and s.c. IL-2. Treatment A consisted of
IFN-a2a and IL-2, only. s.c. IFN-a2a was administered at
5 10
6IUm
 2, day 1, weeks 1+4, and days 1, 3, 5, weeks 2, 3, 5,
6; s.c. IL-2 was administered at 10 10
6IUm
 2, twice daily days
3–5 weeks 1+4, and at 5 10
6IUm
 2, days 1, 3, 5, weeks 2, 3, 5, 6;
weeks 7 and 8 were therapy free. Treatment B consisted of IFN-a2a,
IL-2, and 5-FU. s.c. IFN-a2a was administered at 5 10
6IUm
 2,
day 1, weeks 1+4, and days 1, 3, 5, weeks 2+3, and at
10 10
6IUm
 2, days 1, 3, 5, weeks 5–8. s.c. IL-2 was administered
at 10 10
6IUm
 2, twice daily days 3–5 weeks 1+4, and at
5 10
6IUm
 2, days 1, 3, 5, weeks 2+3; i.v. bolus 5-FU was
administered at 1000mgm
 2, day 1 weeks 5–8. Treatment C
consisted of IFN-a2a, IL-2, 5-FU, and 13-cRA; patients received
20mg p.o. 13cRA twice daily, in addition to the above dosages of
IFN-a2a, IL-2, and 5-FU.
Eight week treatment cycles were repeated for up to three
courses unless progression of disease occurred. Re-evaluation of
patients’ tumour status was performed between treatment cycles.
Concomitant medication was given as needed to control adverse
effects of chemoimmuno-therapy.
Statistical analysis
Survival was measured from start of therapy to date of death or to
the last date known to be alive. Treatment efficacy was assessed on
an intention-to-treat basis. Survival curves were estimated by the
Kaplan–Meier method. Univariate risk factor analysis was
performed by the log-rank test and multivariate analysis by Cox
regression. Continuous pretreatment clinical measurements (e.g.
neutrophil count) were analysed as dichotomous variables
Table 1 Pretreatment clinical factors and their prognostic significance in univariate analysis
Risk factors
a
Categories
compared
Number of
patients
Median survival
(months)
P-value
(log-rank test)
P-value
(corrected
b)
Sex Female vs male 114 vs 311 20 vs 19 0.5
Age (years) o 50 vs X50 80 vs 345 13 vs 21 0.06 0.5
Pretreatment with IL-2 Absent vs present 370 vs 55 20 vs 17 0.6
Time from diagnosis of tumour to metastatic disease (years) o 3 vs X3 304 vs 121 17 vs 25 0.01 0.2
Number of metastatic sites o 3 vs X3 350 vs 75 21 vs 14 o0.001 0.003
Lung metastases Absent vs present 113 vs 312 15 vs 21 0.2
Liver metastases Absent vs present 362 vs 63 20 vs 15 0.03
Lymph node metastases Absent vs present 302 vs 123 21 vs 15 0.02
Brain metastases Absent vs present 400 vs 25 20 vs 20 0.2
Bone metastases Absent vs present 337 vs 88 22 vs 12 o0.001
Other metastases Absent vs present 284 vs 141 21 vs 18 0.2
ESR (mm h
 1)
c o 60 vs X60 343 vs 82 22 vs 11 0.002 0.05
Hemoglobin (gdl
 1)
c o 11 vs X11 48 vs 377 10 vs 21 0.06 0.53
Neutrophil counts (cellsml
 1)
c o 6500 vs X6500 362 vs 63 21 vs 8 o0.001 o0.001
LDH (Ul
 1)
c o 220 vs X220 330 vs 95 22 vs 12 o0.001 0.01
CRP (mgl
 1)
c o 11 vs X11 222 vs 203 24 vs 16 o0.001 o0.001
a Laboratory normal ranges were as follows: ESR: male: 3–8mmh
 1, female: 6–11mmh
 1; haemoglobin: male: 13.5–17.5gdl
 1, female: 12–16gdl
 1; neutrophils: 1500–
7500cellsml
 1; LDH: 80–240Ul
 1; CRP: o5mgl
 1.
b Corrected for testing multiple cutpoints on continuous factors (Miller and Siegmund, 1982).
c Cutoff does not reflect normal range.
Table 2 Multivariate risk factor model for overall survival in metastatic renal carcinoma
Risk factor
Categories
compared Hazard ratio
a 95% CI
a P-value
a
Weight (contribution
to cumulative risk score)
Neutrophil counts (cellsml
 1) o6500 vs X6500 1.9 1.5–2.6 o0.001 0 vs 2
LDH (Ul
 1) o220 vs X220 1.3 1.0–1.7 0.02 0 vs 1
CRP (mgl
 1)
a o11 vs X11 1.4 1.1–1.7 0.001 0 vs 1
Time from diagnosis of tumour to metastatic disease (years) o3 vs X3 0.7 0.5–0.9 0.001 1 vs 0
Number of metastatic sites o3 vs X3 1.4 1.1–1.9 0.01 0 vs 1
Bone metastases Absent vs present 1.5 1.2–2.0 0.001 0 vs 1
aIn multivariate Cox regression model.
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laccording to approximately ‘optimal’ cutpoints, determined as
follows. The value best discriminating between good and poor
survival (i.e., which had the most significant P-value on a log-rank
test) was found by testing all possible cutpoints within the central
80% of the distribution of values. All such cutpoints were then
rounded to clinically relevant (i.e. convenient) values. The P-values
for the clinically relevant cutpoints were corrected for multiple
testing (Miller and Siegmund, 1982; Altman et al, 1994). Cox
regression analysis with forward stepwise variable selection was
employed to build a model with multiple risk factors. To allow for
possible joint effects, all predictors were included as candidate
variables, whether or not significant in univariate analysis.
RESULTS
Median survival time was 20+ months (95% CI, 18, 22; 5-year
survival of 16%) (Figure 3A); 54 of 425 patients remain alive.
Univariate risk factor analysis
As shown in Table 1, we identified the following pretreatment
staging factors as univariate predictors of poor overall survival: (1)
three and more metastatic sites, (2) presence of liver, lymph node
or bone metastases, (3) neutrophil counts X6500cellsml
 1, (4)
serum LDH level X220Ul
 1, and (5) serum C-reactive protein
level (CRP) X11mgl
 1.
Sex, age, time from diagnosis of tumour to metastatic disease,
the presence of lung, brain or other metastases, ESR, haemoglobin
level, and IL-2-pretreatment were also tested, but rendered not
significant by univariate analysis after correction (where neces-
sary) of P-values by using the formula of Miller and Siegmund
(1982) (see also Altman et al, 1994).
Multivariate analysis of risk factors and overall survival
To build a multiple risk factor model, we used multivariate Cox
regression containing all predictors as candidate variables, since
factors that are not univariately significant may nevertheless
become significant when included together in the model. Six
factors were found to be significant in a multivariate fashion.
Neutrophil count was identified as the major prognostic factor
(hazard ratio¼1.9, Po0.001), while serum level of LDH (hazard
ratio 1.3; P¼0.02) and CRP (hazard ratio 1.4; P¼0.001), time
between diagnosis of tumour and metastatic disease (hazard ratio
0.7; P¼0.001), number of metastatic sites (hazard ratio 1.4;
P¼0.01), and bone metastases (hazard ratio 1.5; P¼0.001) were
significant but less important prognostic variables within the
multiple risk factor model (Table 2). However, caution should be
exercised regarding the significance of these P-values since
methodology seems to be unavailable to correct for the selection
of ‘optimal’ cutpoints within a multivariate modelling framework.
The largest and most significant association with an unfavour-
able outcome was observed in patients with elevated neutrophil
count (X6500cellsml
 1) (Figure 1A). A total of 63 patients with
elevated levels of neutrophils count achieved a median overall
survival of 8+ months (95% CI 6, 12; 5-year survival of 3%), while
362 patients with less than 6500cellsml
 1 yielded a median overall
survival of 21+ months (95% CI 19, 24; 5-year survival of 19%).
Similarly, 95 patients with elevated LDH levels yielded a median
overall survival of 12+ months (95% CI 10, 16; 5-year survival of
10%), in contrast to 330 patients with LDH levels less than
220Ul
 1, and a median overall survival of 22+ months (95% CI 19,
25; 5-year survival of 18%).
It was calculated that 203 patients with elevated serum levels of
CRP achieved a median overall survival of 16+ months (95% CI 12,
19; 5-year survival of 9%), while 222 patients with CRP levels less
than 11mgl
 1 yielded a median overall survival of 24+ months
(95% CI 21, 30; 5-year survival of 23%) (Figure 2A). In addition, 75
patients with three and more metastatic sites had a median overall
survival of 14+ months (95% CI 8, 18; 5-year survival of 8%),
compared to 350 patients with one or two metastatic sites and a
median overall survival of 21+ months (95% CI 19, 25; 5-year
survival of 18%) (Figure 2B).
Prognostic system
Based on the rounded regression coefficients (log hazard ratios in
the final Cox model) of variables, we defined the weights of
prognostic features as follows: neutrophil count was assigned
weight 2, the remaining variables (serum level of CRP and LDH,
time between diagnosis of tumour and metastatic disease, number
of metastatic sites, bone metastases) were given weight 1. A
prognostic score consisting of the sum of the weights of these six
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No. of patients at risk
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P
1
2
Months
1:   362   259    165    124      84      54       42      27       14       11        7        2         1        1         
No. of patients at risk 
LDH (< 220)
n = 330  pts.
Median = 22 Months
5-year survival= 18%
1
LDH (220)
n = 95  pts.
Median = 12 Months
5-year survival= 10%
2
A
B
1:   330   236   153     115    78      49       37       24         11       9         7        2         1       1
2:  95      47      28      21      13        7        6   4        3         2        - -- -
Neutrophil counts (6500)
n = 63 pts.
Median = 8 Months
5-year survival= 3%
2
Neutrophil counts (< 6500)
n = 362  pts.
Median = 21 Months
5-year survival = 19%
1
2
1
2:  63     24      16       12     7     2        1        1           ------
1vs   2
Log rank P <  0.001
(corrected)
1vs 2
Log rank P = 0.01
(corrected)
P
Figure 1 Overall survival of 362 patients with neutrophil counts
o6500cellsml
 1 and 63 patients with neutrophil counts X6500cellsml
 1
(A). Overall survival of 330 patients with LDH levels o220Ul
 1 and 95
patients with LDH levels X220Ul
 1 (B). All patients were treated with
outpatient s.c. IL-2/IL-a2a therapy. Survival was calculated from the start of
therapy using Kaplan–Meier method.
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lvariables was used to assign patients to low (0Xscorep1),
intermediate (2Xscorep3), and high risk (4Xscorep7) groups,
respectively (Table 3).
Median overall survival of low (n¼163), intermediate (n¼197),
and high-risk (n¼65) patients was 32+ months (95% CI 24, 43; 5-
year survival of 27%), 18+ months (95% CI 15, 20; 5-year survival
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Median = 14 Months
5-year survival= 8%
2
A
B
1:   350   245     160    123     84       50      38       24     13        10       6  2        1         1
2:  75       38        21      13     7         6         5         4        1         1        1          - - -
n = 203 pts.
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Figure 2 Overall survival of 222 patients with CRP levels o11mgl
 1
and 203 patients with CRP levels X11mgl
 1 (A). Overall survival of 350
patients with o3 metastatic sites and 75 patients with X3 metastatic sites
(B). All patients were treated with outpatient s.c. IL-2/INF-a2a therapy.
Survival was calculated from the start of therapy using Kaplan–Meier
method.
Table 3 Definition of risk groups from cumulative risk score
Risk group Cumulative risk score Contribution of individual prognostic variables
Low risk (n=163) 0, 1 Absence
One minor prognostic variable
a
Intermediate (n=197) 2, 3 Two minor prognostic variables
Three minor prognostic variables
One minor plus major prognostic variable
b
High risk (n=65) 4, 5, 6, 7 Four or five minor prognostic variables
XThree minor plus major prognostic variable
a i.e. with weight 1.
b i.e. with weight 2.
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No. of patients at risk 
Low (0-1)
n = 163  pts.
Median = 32 Months
5-year survival= 27%
1
Intermediate (2-3)
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Median = 18 Months
5-year survival = 11%
2
High (4-7)
n = 65 pts.
Median = 8 Months
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3
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1 vs 3
Log rank P   0.001
2 vs 3
Log rank P < 0.001
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Overall survival 
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P
P
Figure 3 Overall survival of 425 advanced renal-cell carcinoma patients
treated with outpatient s.c. IL-2/INF-a2a therapy (A). Overall survival of
163 low-risk patients, 197 intermediate-risk patients, and 65 high-risk
patients treated with outpatient subcutaneous interleukin-2/interferon-a2a
therapy (B). Survival was calculated from the start of therapy using Kaplan–
Meier method.
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lof 11%), and 8+ months (95% CI 6, 10; 5-year survival of 5%),
respectively (Figure 3B).
DISCUSSION
The objective of this study was to devise a comprehensive new
prognostic system for survival of metastatic renal carcinoma
patients.
Using a multivariate risk model derived from the retrospective
analysis of 425 patients with metastatic renal-cell carcinoma,
we categorised patients into three distinct risk groups based on
the following six prognostic factors for poor survival: (1)
neutrophil count X6500cellsml
1, (2) serum level of LDH
X220Ul
 1, (3) serum level of CRP X11mgl
 1, (4) time between
diagnosis of tumour and metastatic disease less than 3 years, (5)
three and more metastatic sites, and (6) the presence of bone
metastases.
These prognostic variables in advanced renal cancer were
comparable to clinical features reported previously by others,
notably with regard to the number of metastatic sites (Elson et al,
1988), bone metastases (Mani et al, 1995), time between diagnosis
of tumour and metastatic disease (Maldazys and deKernion, 1986;
Elson et al, 1988; Motzer et al, 2002), and serum level of LDH
(Motzer et al, 1999, 2002).
In this current and in our previous study (Lopez-Ha ¨nninen et al,
1996), for the first time, we could identify pretreatment neutrophil
count as a highly statistically significant predictor for overall
survival in advanced renal-cell carcinoma. While the biological
interpretation of increased neutrophil counts is not evident, Blay
et al (1997) demonstrated that IL-6 associated neutrophilia in
renal-cell carcinoma could be decreased via the suppression of IL-
6 or IL-6-associated paraneoplastic inflammatory syndrome in
renal carcinoma. Notably, Paesmans et al (1995, 2000) and Kapp
et al (1983) also showed its impact as a prognostic factor for
survival in small-cell lung cancer and uterine cervix carcinoma,
respectively.
Surprisingly, in this report the presence of brain or CNS
metastases (n¼25) had no selective impact on survival, which may
have been because of concomitant extensive multiorgan disease.
Alternatively, the small number of such patients may have reduced
the statistical power to detect such an impact in the presence of
other important risk factors.
Similar to Motzer et al (2002), who categorised IFN-a-treated
advanced renal-cell cancer patients into three different groups with
low (18%; overall survival 30 months), intermediate (62%; overall
survival 14 months), and high-risk patients (20%; overall survival 5
months), respectively, we established three distinct survival
subgroups that is, low-risk patients (38%) with an overall median
survival of 32 months, intermediate-risk patients (47%) with an
overall median survival of 18 months, and high-risk patients (15%)
with an overall median survival of 8 months. Notably, while
Motzer et al (2002) also included LDH, in our current model,
performance status and serum calcium were not tested, and serum
haemoglobin was not identified as a significant statistical predictor
for overall survival. In the present prognostic model, risk groups
exhibited well-separated survival curves that reflected the prog-
nosis of good/excellent performance status of metastatic renal-cell
carcinoma patients receiving outpatient IL-2/IFN-a2a. Overall, this
group was highly selected as demonstrated by the relatively large
number of patients who had a delay between primary diagnosis
and metastatic disease in excess of 3 years.
The identification of prognostic features for overall survival in
metastatic renal carcinoma patients has a pivotal role in defining
future individualised molecular treatment approaches. The low
proportion of patients achieving long-term survival suggest the
need for further clinical trials of new therapeutic agents.
While there is a partial consensus between different prognostic
models in metastatic renal-cell carcinoma, validation of our
proposed model will require testing in a prospectively designed
study.
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